U.S. markets closed
  • S&P 500

    3,621.63
    -16.72 (-0.46%)
     
  • Dow 30

    29,638.64
    -271.73 (-0.91%)
     
  • Nasdaq

    12,198.74
    -7.11 (-0.06%)
     
  • Russell 2000

    1,819.82
    -35.45 (-1.91%)
     
  • Crude Oil

    45.27
    -0.07 (-0.15%)
     
  • Gold

    1,781.10
    +0.20 (+0.01%)
     
  • Silver

    22.73
    +0.14 (+0.61%)
     
  • EUR/USD

    1.1943
    +0.0009 (+0.07%)
     
  • 10-Yr Bond

    0.8440
    +0.0020 (+0.24%)
     
  • GBP/USD

    1.3339
    +0.0008 (+0.06%)
     
  • USD/JPY

    104.3550
    +0.0310 (+0.03%)
     
  • BTC-USD

    19,529.20
    +11.93 (+0.06%)
     
  • CMC Crypto 200

    382.09
    +17.50 (+4.80%)
     
  • FTSE 100

    6,266.19
    -101.39 (-1.59%)
     
  • Nikkei 225

    26,433.62
    0.00 (0.00%)
     

Why the Earnings Streak Will Continue for Intra-Cellular (ITCI)

Zacks Equity Research

Looking for a stock that might be in a good position to beat earnings at its next report? Consider Intra-Cellular Therapies, Inc. (ITCI), a firm in the biopharmaceutical industry, which could be a great candidate for another beat.

This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. In fact, in these reports, ITCI has beaten estimates by at least 10.0% in both cases, suggesting it has a nice short-term history of crushing expectations.

Earnings in Focus

Two quarters ago, ITCI expected to report a loss of 41 cents per share, while it actually produced loss of 36 cents per share, a beat of 12.2%. Meanwhile, for the most recent quarter, the company looked to report loss of 23 cents per share, when it actually saw loss of 17 cents per share instead, representing a 26.1% positive surprise.

Thanks in part to this history, recent estimates have been moving higher for Intra-Cellular. In fact, the Earnings ESP for ITCI is positive, which is a great sign of a coming beat.

After all, the Zacks Earnings ESP compares the most accurate estimate to the broad consensus, looking to find stocks that have seen big revisions as of late, suggesting that analysts have recently become more bullish on the company’s earnings prospects. This is the case for ITCI, as the firm currently has a Zacks Earnings ESP of 4.00%, so another beat could be around the corner.

This is particularly true when you consider that ITCI has a great Zacks Rank #2 (Buy) which can be a harbinger of outperformance and a signal for a strong earnings profile. And when you add this solid Zacks Rank to a positive Earnings ESP, a positive earnings surprise happens nearly 70% of the time, so it seems pretty likely that ITCI could see another beat at its next report, especially if recent trends are any guide.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>




INTRA CELLULAR THERAPIES INC (ITCI): Free Stock Analysis Report


Zacks Investment Research